What is the recommended antiviral treatment regimen for genital herpes (herpes genitalis)?

Genital Herpes Treatment Recommendations

For first clinical episode genital herpes, treat with valacyclovir 1 g orally twice daily for 7-10 days, which offers superior convenience and adherence compared to acyclovir while maintaining equivalent efficacy. 1

Treatment by Clinical Scenario

First Clinical Episode (Primary Infection)

The most practical regimens based on dosing convenience are 1:

• Valacyclovir 1 g orally twice daily for 7-10 days (preferred for adherence)
• Acyclovir 400 mg orally three times daily for 7-10 days
• Famciclovir 250 mg orally three times daily for 7-10 days

Extend treatment beyond 10 days if healing is incomplete. 1 The 1998 CDC guidelines introduced valacyclovir and famciclovir as alternatives to the older acyclovir-only regimens from 1993, providing more convenient dosing schedules that improve real-world adherence 2, 1.

Special consideration for herpes proctitis: Higher doses may be needed—acyclovir 400 mg orally five times daily for 10 days was used in treatment studies, though clinical experience with valacyclovir/famciclovir for this indication is limited 1.

Recurrent Episodes - Episodic Therapy

Treatment must be initiated during prodrome or within 1 day of lesion onset to provide benefit 1. Provide patients with medication or a prescription in advance so they can self-initiate treatment immediately.

Recommended regimens for episodic treatment 1:

• Valacyclovir 500 mg orally twice daily for 5 days (most convenient)
• Acyclovir 800 mg orally twice daily for 5 days
• Acyclovir 400 mg orally three times daily for 5 days
• Famciclovir 125 mg orally twice daily for 5 days

Recurrent Episodes - Suppressive Therapy

Suppressive therapy should be offered to all patients with symptomatic HSV-2 infection 3, as it reduces recurrence frequency by ≥75% and decreases transmission risk to uninfected partners 1.

Indications for suppressive therapy:

• Six or more recurrences per year (classic indication) 1
• Any patient with symptomatic HSV-2 who wants to reduce transmission risk 3
• Significant psychosocial impact from recurrences

Recommended suppressive regimens 1:

• Valacyclovir 500 mg orally once daily (most convenient for adherence)
• Valacyclovir 1,000 mg orally once daily
• Acyclovir 400 mg orally twice daily
• Famciclovir 250 mg orally twice daily

Critical caveat: Valacyclovir 500 mg once daily is less effective in patients with ≥10 recurrences per year—use higher doses or twice-daily regimens in this population 1.

Duration and reassessment: After 1 year of continuous suppressive therapy, discuss discontinuation to reassess recurrence frequency, as this naturally decreases over time 1. Safety data support acyclovir use for up to 6 years and valacyclovir/famciclovir for at least 1 year 1.

Severe Disease Requiring Hospitalization

For disseminated infection, encephalitis, pneumonitis, hepatitis, or CNS complications:

• Acyclovir 5-10 mg/kg IV every 8 hours for 5-7 days or until clinical resolution 1

This applies to immunocompetent patients with severe presentations and immunocompromised patients with extensive disease 2.

HSV-1 vs HSV-2 Management Differences

Important distinction: Although genital HSV-1 has not been studied as comprehensively as HSV-2, the same medication dosages and frequencies are recommended 3. However, HSV-1 genital infection recurs far less frequently than HSV-2, so suppressive therapy is less commonly needed for HSV-1 3.

Special Populations

Pregnancy

For first episode during pregnancy:

• Acyclovir 200 mg orally 5 times daily for 5-10 days, OR
• Valacyclovir 1000 mg orally twice daily for 5-10 days 4, 5

Suppressive therapy from 36 weeks gestation until delivery (to reduce need for cesarean section due to active lesions at delivery) 4, 5:

• Acyclovir 400 mg orally three times daily, OR
• Valacyclovir 500 mg orally twice daily

Cesarean delivery is indicated if:

• Active lesions present at onset of labor 5
• First episode occurred <6 weeks before delivery 5

HIV/Immunocompromised Patients

These patients may require longer treatment courses and closer monitoring 2. Acyclovir-resistant strains can emerge, requiring alternative antiviral agents 2.

Critical Counseling Points

All patients must be counseled on 1:

• Asymptomatic viral shedding occurs and is the primary mode of transmission—most cases are transmitted when no lesions are present
• Abstain from sexual activity when lesions or prodromal symptoms present
• Condom use during all sexual exposures with new/uninfected partners
• HSV-2 sheds more frequently than HSV-1, especially in the first 12 months after infection 1
• Suppressive therapy reduces but does not eliminate asymptomatic shedding 1
• Neonatal transmission risk—women of childbearing age must inform prenatal care providers 1

Common Pitfalls to Avoid

1. Don't use topical acyclovir—it is substantially less effective than oral therapy and is discouraged 2

2. Don't delay episodic treatment—efficacy depends on starting within 1 day of symptom onset; provide advance prescriptions 1

3. Don't forget to type the virus—HSV-1 vs HSV-2 distinction affects recurrence counseling and management decisions 3

4. Don't screen asymptomatic low-risk individuals—serologic testing has limitations and routine screening is not recommended 3

5. Don't use valacyclovir 500 mg once daily for patients with ≥10 recurrences/year—this dose is insufficient 1